Free Newsletter
Dynavax inks universal vaccine pact with Novartis
Dynavax Technologies and Novartis Vaccines and Diagnostics are teaming up on an effort to develop a new universal flu vaccine. Novartis Vaccines, which includes the old Chiron ops it bought out, will provide a trivalent flu vaccine to Dynavax for use in the universal vaccine in exchange for an exclusive option to negotiate a licensing deal. No financial details were divulged in their announcement.
Vaccine makers have been scrambling to come up with a universal flu vaccine that can defend against a variety of flu strains. Every year health officials target three strains--a guessing game that often misses the mark. A universal vaccine would help remove some of that guesswork and do a much better job at protecting populations
- read the report from the San Francisco Business Times
Related Articles:
Universal flu vaccine shows early promise
Acambis researching single-shot solution to flu
VaxInnate in a race to produce 'universal' flu vaccine
Comments
Post new comment
Paid Research Reports
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Pharmaceutical Licensing Overview
- Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina
- Pharmaceutical Key Trends 2010
- Commercial Insight: Top 20 Oncology Therapy Brands in Australia
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities


SHARE
WITH: